An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications

LJ Shih, CC Yang, MT Liao, KC Lu, WC Hu, CP Lin - Virulence, 2023 - Taylor & Francis
The global coronavirus disease 2019 (COVID-19) pandemic has a detrimental impact on
public health. COVID-19 usually manifests as pneumonia, which can progress into acute …

[HTML][HTML] The role of IL-6 in coronavirus, especially in COVID-19

X Wang, G Tang, Y Liu, L Zhang, B Chen… - Frontiers in …, 2022 - frontiersin.org
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects both people and
animals and may cause significant respiratory problems, including lung illness: Corona …

The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics

M Abbasifard, H Khorramdelazad - Life sciences, 2020 - Elsevier
Abstract Interleukin-6 (IL-6), known as an inflammatory cytokine, can be involved in many
innate and adaptive immune responses. The role of IL-6 in the pathogenesis of the novel …

[PDF][PDF] Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy

P Conti, A Caraffa, CE Gallenga, R Ross… - J Biol Regul Homeost …, 2020 - researchgate.net
SARS-Cov-2 infection causes local and systemic inflammation mediated by pro-
inflammatory cytokines and COX-2 eicosanoid products with metabolic dysfunction and …

Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy

T Shibabaw - Journal of inflammation research, 2020 - Taylor & Francis
Abstract Coronavirus disease 2019 (COVID-19) is a globally communicable public health
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2) …

[HTML][HTML] Anti-IL6R role in treatment of COVID-19-related ARDS

FM Buonaguro, I Puzanov, PA Ascierto - Journal of translational medicine, 2020 - Springer
SARS-CoV-2 infection is not like the seasonal flu. While the range of symptoms for the two
viruses is similar, the fraction with severe disease appears to be different. For COVID-19 …

May IL-17 have a role in COVID-19 infection?

M Megna, M Napolitano, G Fabbrocini - Medical hypotheses, 2020 - ncbi.nlm.nih.gov
SARS-Corona-Virus-2 related disease (COVID-19) which started in Wuhan, China on
December 2019, is spreading rapidly throughout the world [1]. COVID-19 clinical spectrum is …

The role of interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19

I Giannakodimos, GV Gkountana… - Current Medicinal …, 2021 - ingentaconnect.com
A newly identified virus appeared in Wuhan, China, in December 2019, was named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and caused the coronavirus …

Interleukin-17: A potential therapeutic target in COVID-19

VMM Mendoza - Journal of Infection, 2020 - journalofinfection.com
In a recent review, Ye and colleagues discussed in this journal the inflammatory response
mechanisms underlying the coronavirus disease 2019 (COVID-19) caused by severe acute …

[HTML][HTML] COVID-19 infection: an overview on cytokine storm and related interventions

S Montazersaheb, SM Hosseiniyan Khatibi, MS Hejazi… - Virology journal, 2022 - Springer
Abstract Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has posed a significant threat to global health. This …